Newly published preclinical research signals a substantial conceptual shift with a potential role of photon-counting CT in targeting specific biological processes.
|Articles|October 31, 2001
Vital Images licenses colonoscopy software
Medical imaging software company Vital Images has obtained a nonexclusive license from Winston-Salem, NC-based PointDx for patents related to virtual endoscopy. Access to the technology will allow Vital Images to enhance its CT colonoscopy technology in
Advertisement
Medical imaging software company Vital Images has obtained a nonexclusive license from Winston-Salem, NC-based PointDx for patents related to virtual endoscopy. Access to the technology will allow Vital Images to enhance its CT colonoscopy technology in Vitrea 2, the company’s flagship software product.
Advertisement
Related to this article
The future of AI in radiology lies in its potential capability to forge connections and enhance efficiencies for enterprise-wide workflows.
In a new podcast episode, Joseph Cavallo, MD, MBA, offered his perspective on AI integration, potential efficiency gains, navigating post-deployment monitoring and how to incorporate AI literacy into radiology resident training.
The FFR-IQ software recently demonstrated a 92.2 percent sensitivity for non-invasive estimation of fractional flow reserve (FFRC) based on coronary CT angiography (CCTA) scans.
A Kaiser score > 5 with breast MRI demonstrated a 97 percent sensitivity and 87.9 percent specificity for predicting malignancy in patients with BI-RADS 0 or 4 presentations on mammography and breast ultrasound, according to a new study.
In a recent interview, Francesco Giganti, MD, PhD, discussed findings from a recent multicenter study demonstrating the ability of an AI software to provide significant clarity to initial PI-RADS 3 assessments on MRI and facilitate a nearly 19 percent reduction in unnecessary prostate biopsies.
The NEXT-Cue AI software, which incorporates analysis of brain MRI scans, reportedly facilitates prognostic assessments of potential progression from mild cognitive impairment (MCI) to Alzheimer’s disease within five years.
In a new podcast episode, Amir Iravani, MD, FRACP, discusses emerging dosimetry data from the COMPETE trial for 177Lu-edotreotide and how it may help facilitate more personalized treatment for patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
Advertisement
Advertisement
Trending on Diagnostic Imaging
1
FDA Clears MRI-Based AI Software for Prognostic Evaluation of Patients with Mild Cognitive Impairment
2
How AI, Theranostics and More Empowered Patients Have Led to Significant Changes in Radiology
3
What’s Next for AI in Radiology?: Facilitating Data Orchestration Over Fragmentation
4
FDA Clears AI-Enabled FFR-IQ Software for Estimating Fractional Flow Reserve from CCTA
5